This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB04892/identifier/bindingdb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB04892/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04892/identifier/pubchem-substance/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04892/identifier/drugbank/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04892/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB04892
rdf:type
n3:Drug
n3:description
Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. Unlike currently marketed AChE inhibitors, it has a dual mechanism of action that also includes anti-amyloid activity, which may confer disease-modifying effects in patients with AD. If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.
n3:generalReferences
# Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR Jr, Canfield CJ, Burford RG: Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res. 2005 Oct;2(4):483-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16248851 # Klein J: Phenserine. Expert Opin Investig Drugs. 2007 Jul;16(7):1087-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17594192 # Thatte U: Phenserine (Axonyx/NIH). IDrugs. 2000 Oct;3(10):1222-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16049844
n3:group
investigational
n3:halfLife
8 to 10 hours
n3:indication
For the treatment of Alzheimer's disease (AD).
owl:sameAs
n13:DB04892
dcterms:title
Phenserine
adms:identifier
n6:10958 n7:192706 n8:14900124 n9:167225 n10:DB04892
n3:mechanismOfAction
Phenserine is a highly selective, reversible acetylcholinesterase inhibitor, a mechanism of action known to improve memory and cognition in Alzheimer’s subjects. Phenserine may prove to concentrate in the brain rapidly which would reduce the incidence of drug toxicity and side effects.
n3:synonym
(-)-phenserine (-)-eseroline phenylcarbamate
n3:toxicity
The toxicity of phenserine, a derivate of physostigmine, is dramatically less. Doses of 20 mg/kg (rats, intravenous) of phenserine have not been associated with toxicity or deaths.
n3:IUPAC-Name
n4:271B5DAE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DB4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DB3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5DB0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5DB1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DB2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5DAC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5DAD-363D-11E5-9242-09173F13E4C5 n4:271B5DAA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5DAB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5DBA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DBB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DB5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DB6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DB8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DB7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DB9-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed and cleared from the body.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
101246-66-6
n3:Bioavailability
n4:271B5DC0-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DC2-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DC3-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5DC4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DBF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DBE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DC1-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5DAF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DBC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DBD-363D-11E5-9242-09173F13E4C5